AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33712080 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA) using dexmedetomidine and lidocaine
Number of subjects: 78
Study 33712080 — intervention group
Group type: COMPARATOR
Intervention: Standard general anesthesia using remifentanil
Number of subjects: 78
Study 32827458 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention for intensive BP treatment including protocol‐based treatment using the SPRINT intensive BP management algorithm, dissemination of SPRINT findings, BP audit and feedback, home BP monitoring, and health coaching.
Number of subjects: 1260
Study 32827458 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 1260
Study 32827458 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention for intensive BP treatment
Number of subjects: 1260
Study 36228984 — intervention group
Group type: EXPERIMENTAL
Intervention: ZSQI plus a stepped care intervention for suicide prevention (SC-SP)
Number of subjects: 300
Study 36228984 — intervention group
Group type: COMPARATOR
Intervention: Zero Suicide Quality Improvement (ZSQI)
Number of subjects: 300
Study 33331495 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐BBI‐I
Number of subjects: 45
Study 33331495 — intervention group
Group type: COMPARATOR
Intervention: CBT‐I
Number of subjects: 45
Study 35368119 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear mixed effects models (LMMs) for handling missing data
Number of subjects: 0
Study 35368119 — intervention group
Group type: COMPARATOR
Intervention: Multiple imputation methods
Number of subjects: 0
Study 33245245 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep education and PHM intervention
Number of subjects: 24
Study 33245245 — intervention group
Group type: COMPARATOR
Intervention: Sleep education only
Number of subjects: 24
Study 32299120 — intervention group
Group type: EXPERIMENTAL
Intervention: Real AMPS
Number of subjects: 25
Study 32299120 — intervention group
Group type: COMPARATOR
Intervention: Placebo AMPS
Number of subjects: 25
Study 35238969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose (ULD) CT
Number of subjects: 63
Study 35238969 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (SD) CT
Number of subjects: 63
Study 33574163 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antibiotic prescription (IAP)
Number of subjects: 436
Study 33574163 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescription (DAP)
Number of subjects: 436
Study 33574163 — intervention group
Group type: EXPERIMENTAL
Intervention: No antibiotic prescription (NAP)
Number of subjects: 436
Study 34872441 — intervention group
Group type: EXPERIMENTAL
Intervention: SOCS‐2 gene expression at diagnosis in blast crisis patients
Number of subjects: 123
Study 34872441 — intervention group
Group type: COMPARATOR
Intervention: SOCS‐2 gene expression at diagnosis
Number of subjects: 123
Study 33301246 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (30 μg per dose, two doses, 21 days apart)
Number of subjects: 43448
Study 33301246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43448
Study 33301246 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 43448
Study 35279718 — intervention group
Group type: EXPERIMENTAL
Intervention: EV 2 mg + DNG 2-3 mg
Number of subjects: 59
Study 35279718 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 0.03 mg + DNG 2 mg
Number of subjects: 59
Study 35279718 — intervention group
Group type: COMPARATOR
Intervention: DNG 2 mg
Number of subjects: 59
Study 34338369 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth
Number of subjects: 0
Study 34338369 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 34910089 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein low-glycemic index diet (HPLGI: 25%-28% of energy from protein, glycemic index ≤ 55)
Number of subjects: 279
Study 34910089 — intervention group
Group type: COMPARATOR
Intervention: Moderate-protein moderate-glycemic index diet (MPMGI: 15%-18% of energy from protein, glycemic index ∼60)
Number of subjects: 279
Study 34910089 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein low-glycemic index diet (HPLGI)
Number of subjects: 279
Study 34910089 — intervention group
Group type: COMPARATOR
Intervention: Moderate-protein moderate-glycemic index diet (MPMGI)
Number of subjects: 279
Study 32852904 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine (52.5 mg)
Number of subjects: 154
Study 32852904 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric Bupivacaine (11.25 mg)
Number of subjects: 154
Study 32852904 — intervention group
Group type: COMPARATOR
Intervention: Isobaric Bupivacaine (12.5 mg)
Number of subjects: 154
Study 36151010 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Hz stimulation
Number of subjects: 14
Study 36151010 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 Hz stimulation
Number of subjects: 14
Study 36151010 — intervention group
Group type: COMPARATOR
Intervention: 10,000 Hz stimulation
Number of subjects: 14
Study 36151010 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 14
Study 33980995 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and vitamin D 4000 IU/d
Number of subjects: 62
Study 33980995 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D 1200 IU/d (Control)
Number of subjects: 62
Study 32378654 — intervention group
Group type: EXPERIMENTAL
Intervention: IGB plus low-carbohydrate diet
Number of subjects: 31
Study 32378654 — intervention group
Group type: COMPARATOR
Intervention: IGB plus calorie-restricted diet
Number of subjects: 31
Study 35905197 — intervention group
Group type: EXPERIMENTAL
Intervention: NXT15906F6 (2.5 gram/day)
Number of subjects: 22
Study 35905197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 34243719 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum block combined with fascia iliaca compartment block (group QF)
Number of subjects: 54
Study 34243719 — intervention group
Group type: COMPARATOR
Intervention: Transmuscular quadratus lumborum block (group Q)
Number of subjects: 54
Study 33464318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus best supportive care
Number of subjects: 413
Study 33464318 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 413
Study 35064175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise (CE) intervention for 2 weeks
Number of subjects: 0
Study 35064175 — intervention group
Group type: COMPARATOR
Intervention: Non-CE control group
Number of subjects: 0
Study 34729326 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique Axis (OAX)
Number of subjects: 210
Study 34729326 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Axis (LAX)
Number of subjects: 210
Study 34729326 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Axis (SAX)
Number of subjects: 210
Study 36194352 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-based regimen
Number of subjects: 29463
Study 36194352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29463
Study 33779480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention (EMI)
Number of subjects: 55
Study 33779480 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 55
Study 32923417 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic-Workshop (one-time 90-min workshop in rope skipping)
Number of subjects: 486
Study 32923417 — intervention group
Group type: EXPERIMENTAL
Intervention: Champion-Program (10 lessons in rope skipping)
Number of subjects: 486
Study 32923417 — intervention group
Group type: COMPARATOR
Intervention: Control group (78 students)
Number of subjects: 486
Study 35568489 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Culturally Adapted Manual Assisted Problem Solving Training (YCMAP) - 8-10 individual sessions over 3 months
Number of subjects: 652
Study 35568489 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 652
Study 32330971 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion group (affected leg elevated by 30 degrees at the hip and knee flexed by 30 degrees postoperatively)
Number of subjects: 0
Study 32330971 — intervention group
Group type: COMPARATOR
Intervention: Extension group (affected knee fully extended postoperatively)
Number of subjects: 0
Study 32330971 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study 32623375 — intervention group
Group type: COMPARATOR
Intervention: Arousal index in overweight/obese prepubertal children
Number of subjects: 151
Study 32623375 — intervention group
Group type: COMPARATOR
Intervention: Minimum O2 saturation in overweight/obese prepubertal children
Number of subjects: 151
Study 32623375 — intervention group
Group type: COMPARATOR
Intervention: Apnea-hypopnea index in overweight/obese pubertal children
Number of subjects: 151
Study 32623375 — intervention group
Group type: COMPARATOR
Intervention: pCO2 in overweight/obese pubertal children
Number of subjects: 151
Study 35725632 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) plus sterile water
Number of subjects: 126
Study 35725632 — intervention group
Group type: COMPARATOR
Intervention: 24% oral sucrose
Number of subjects: 126
Study 32631820 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (PZQ)
Number of subjects: 45
Study 35791269 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine group from the PARAMEDIC2 trial
Number of subjects: 26019
Study 35791269 — intervention group
Group type: COMPARATOR
Intervention: Baseline variables in a German EMS and health care system
Number of subjects: 26019
Study 35791269 — intervention group
Group type: COMPARATOR
Intervention: Baseline plus treatment model in a German EMS and health care system
Number of subjects: 26019
Study 33858875 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth programme comprising balance exercise, cognitive‐motor exercise and cognitive‐behavioural therapy
Number of subjects: 518
Study 33858875 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth programme
Number of subjects: 518
Study 33858875 — intervention group
Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 518
Study 32163721 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner's scent
Number of subjects: 155
Study 32163721 — intervention group
Group type: COMPARATOR
Intervention: Control scent
Number of subjects: 155
Study 36150846 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation (HFS) technology
Number of subjects: 68
Study 36150846 — intervention group
Group type: COMPARATOR
Intervention: Traditional learning methods (Control)
Number of subjects: 68
Study 35134697 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate supplement for 4 weeks
Number of subjects: 78
Study 35134697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 33950030 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral conjugated equine estrogen (CEE) (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) for women with a uterus (5.7 years)
Number of subjects: 27347
Study 33950030 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral CEE (0.625 mg) alone for women with a hysterectomy (7.2 years)
Number of subjects: 27347
Study 33950030 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk scores (AHA/ACC and Framingham Heart Study)
Number of subjects: 27347
Study 33950030 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and years since menopause
Number of subjects: 27347
Study 32811740 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Care
Number of subjects: 0
Study 32811740 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional one-to-one care)
Number of subjects: 0
Study 33836826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (300 mcg/kg) administered daily for three consecutive days
Number of subjects: 186
Study 33836826 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered daily for three consecutive days
Number of subjects: 186
Study 33635540 — intervention group
Group type: EXPERIMENTAL
Intervention: SUP (pantoprazole)
Number of subjects: 3291
Study 33635540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3291
Study 32176305 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgender woman identification
Number of subjects: 297
Study 32176305 — intervention group
Group type: COMPARATOR
Intervention: Smoking cigarettes monthly or less
Number of subjects: 297
Study 32176305 — intervention group
Group type: COMPARATOR
Intervention: Smoking cigarettes daily
Number of subjects: 297
Study 32176305 — intervention group
Group type: COMPARATOR
Intervention: Identifying as a sexual orientation other than heterosexual, gay, lesbian, or bisexual
Number of subjects: 297
Study 35416163 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (anterior‐superior RCT type 1,2,3 or combination)
Number of subjects: 136
Study 35416163 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (posterior‐superior RCT type 3, 4, 5 or combination)
Number of subjects: 136
Study 35416163 — intervention group
Group type: COMPARATOR
Intervention: Control group (different shoulder surgery)
Number of subjects: 136
Study 33249482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR) condition: participants slept from 0300-0700 hours for three nights followed by a recovery night of 8-h sleep, repeated four times.
Number of subjects: 45
Study 33249482 — intervention group
Group type: COMPARATOR
Intervention: Control: Eight-hour sleep per night.
Number of subjects: 45
Study 33249482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR) condition
Number of subjects: 45
Study 33249482 — intervention group
Group type: EXPERIMENTAL
Intervention: Control and Sleep restriction (SR) condition
Number of subjects: 45
Study 35791906 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use days
Number of subjects: 99
Study 35791906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use days
Number of subjects: 99
Study 35791906 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily co-use of alcohol and cannabis
Number of subjects: 99
Study 35791906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling co-use days
Number of subjects: 99
Study 34668237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair lotion containing creatine, acetyl tetrapeptide‐2 and B vitamins with mild shampoo
Number of subjects: 100
Study 34668237 — intervention group
Group type: COMPARATOR
Intervention: Mild shampoo alone (control)
Number of subjects: 100
Study 35584801 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of waist circumference (WC) variability
Number of subjects: 10001
Study 35584801 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of body mass index (BMI) variability
Number of subjects: 10001
Study 35584801 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of BMI variability
Number of subjects: 10001
Study 35584801 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of BMI variability
Number of subjects: 10001
Study 34583667 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning group
Number of subjects: 0
Study 34583667 — intervention group
Group type: COMPARATOR
Intervention: Scale group
Number of subjects: 0
Study 32672584 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 trabecular micro-bypass stents (iStent trabecular micro-bypass; Glaukos Corporation)
Number of subjects: 101
Study 32672584 — intervention group
Group type: COMPARATOR
Intervention: Topical travoprost (once-daily)
Number of subjects: 101
Study 33843490 — intervention group
Group type: EXPERIMENTAL
Intervention: Move in office with education (MOWE)
Number of subjects: 46
Study 33843490 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 46
Study 33441359 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based cigarette smoking cessation smartphone app intervention
Number of subjects: 1200
Study 33441359 — intervention group
Group type: COMPARATOR
Intervention: Text messaging-based control intervention
Number of subjects: 1200
Study 33342719 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive and tailored short message reminders
Number of subjects: 209
Study 33342719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 209
Study 35410489 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative score based on hemoglobin (HB), C-reactive protein to albumin ratio (CAR), and platelet to lymphocyte ratio (PLR)
Number of subjects: 421
Study 35410489 — intervention group
Group type: EXPERIMENTAL
Intervention: COHCP-based nomogram
Number of subjects: 421
Study 33797667 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 635
Study 33797667 — intervention group
Group type: EXPERIMENTAL
Intervention: Hopelessness
Number of subjects: 635
Study 33797667 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-concept
Number of subjects: 635
Study 35256599 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 51
Study 35256599 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study 33048319 — intervention group
Group type: EXPERIMENTAL
Intervention: My eReport France® App (experimental arm)
Number of subjects: 159
Study 33048319 — intervention group
Group type: COMPARATOR
Intervention: Traditional reporting (control arm)
Number of subjects: 159
Study 35786739 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical Whipple
Number of subjects: 84
Study 35786739 — intervention group
Group type: COMPARATOR
Intervention: PPPD (control group)
Number of subjects: 84
Study 34879480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse‐delivered care transition intervention
Number of subjects: 512
Study 34879480 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 512
Study 35019976 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry-measured moderate-to-vigorous physical activity (MVPA)
Number of subjects: 1978
Study 35019976 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA accumulated in ≥10-min bouts
Number of subjects: 1978
Study 35019976 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity
Number of subjects: 1978
Study 35019976 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry-measured MVPA at 1 year
Number of subjects: 1978
Study 33270930 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based multicomponent intervention to prevent physical restraints
Number of subjects: 0
Study 32883333 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) 0.5 mg/kg twice a day for 7 days, then 0.5 mg/kg once a day for 3 days
Number of subjects: 0
Study 32883333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same volume as HC)
Number of subjects: 0
Study 32883333 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC)
Number of subjects: 0
Study 32883333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35197358 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin (AL)
Number of subjects: 500
Study 35197358 — intervention group
Group type: COMPARATOR
Intervention: Psoralen combined with ultraviolet A (PUVA)
Number of subjects: 500
Study 34790015 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon
Number of subjects: 139
Study 34790015 — intervention group
Group type: COMPARATOR
Intervention: nucleos(t)ide analog (NUC)-based therapy
Number of subjects: 139
Study 34790015 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum qHBcrAg
Number of subjects: 139
Study 34790015 — intervention group
Group type: EXPERIMENTAL
Intervention: Log HBcrAg at week 24
Number of subjects: 139
Study 34790015 — intervention group
Group type: EXPERIMENTAL
Intervention: Log HBcrAg at week 48
Number of subjects: 139
Study 34790015 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum HBcrAg levels
Number of subjects: 139
Study 32512314 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseload midwifery
Number of subjects: 1019
Study 32512314 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1019
Study 36004722 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises (diaphragmatic and pursed lip breathing) performed for 10-15 minutes every morning/evening for eight weeks.
Number of subjects: 0
Study 36004722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 0
Study 36029512 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol
Number of subjects: 66
Study 36029512 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 66
Study 33901508 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tensile strength tape with Krackow stitch
Number of subjects: 84
Study 33901508 — intervention group
Group type: COMPARATOR
Intervention: High-tensile strength suture with Krackow stitch
Number of subjects: 84
Study 33901508 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tensile strength tape with whip stitch
Number of subjects: 84
Study 33901508 — intervention group
Group type: COMPARATOR
Intervention: High-tensile strength suture with whip stitch
Number of subjects: 84
Study 35177084 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-Y-5L
Number of subjects: 83
Study 35177084 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D-Y-3L
Number of subjects: 83
Study 34239941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeplessness
Number of subjects: 0
Study 34239941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 0
Study 34239941 — intervention group
Group type: COMPARATOR
Intervention: Chronotype, getting up in the morning, nap during the day
Number of subjects: 0
Study 34239941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeplessness and sleep duration (in multivariate MR analysis)
Number of subjects: 0
Study 35159306 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Drink (ED)
Number of subjects: 26
Study 35159306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 32851411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF plus Fluarix
Number of subjects: 180
Study 32851411 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Fluarix
Number of subjects: 180